10th ESO-ESMO Masterclass in Clinical Oncology

Chair: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Coordinators: W. Gatzemeier, IT - R. Popescu, CH 

The Masterclass in Clinical Oncology is an ESO-ESMO joint event

The masterclass is held in collaboration with the Flims Alumni Club

ORGANISING SECRETARIAT
Chatrina Melcher
European School of Oncology - Bellinzona Office
Ospedale Regionale Bellinzona e Valli
CH6500 Bellinzona - Switzerland
Tel: +41 91 811 8050
Fax: +4191 811 8051
Email: cmelcher@eso.net



CME ACCREDITATION
The 10th ESO-ESMO Masterclass in Clinical Oncology has been appraised and approved by the Accreditation Council of Oncology in Europe (ACOE). ACOE accreditation acknowledges the quality of the scientific programme and its educational value. ACOE is a multidisciplinary body of full time specialists practising in the field of oncology and all recognised for their experience in education and expertise in their field. 
ACOE accreditation has been endorsed by the European Accreditation Council for Continuing Medical Education (EACCME) – an institution of the European Union of Medical Specialists (UEMS) – to provide the mentioned CME activity for medical specialists.
The Masterclass is designated for a maximum of 27 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.
The Masterclass has furthermore been accredited with 25 ESMO-MORA points Cat. 1.

 

ACKNOWLEDGEMENTS
ESO wishes to express its appreciation to Union Bank of Switzerland (UBS) and Wolfsberg Centre for their consideration and support to the 2011 Masterclass.

The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are:

- Platinum members: Amgen and Eisai
- Gold members: Eli Lilly, GlaxoSmithKline Oncology and Merck Serono
- Silver members: Genomic Health, Novartis Oncology and Sanofi-Aventis

FACULTY

M. Aapro, IMO Clinique de Genolier, FMH Oncologie-Hématologie, Genolier, CH
M.R. Alison, Barts and the London School of Medicine and Dentistry, Institute of Cell and Molecular Science, Centre for Diabetes, London UK
R. Beets-Tan, Maastricht University Medical Center, Department of Radiology, Maastricht, NL
J. Bernier, Genolier Swiss Medical Network, Department of Radiotherapy, Genolier, CH
F. Blackhall, The Christie NHS Foundation Trust, CRC Department of  Medical Oncology, Manchester, UK
P. Casali, National Cancer Institute, Department of Medical Oncology, Milano, IT
G. Curigliano, European Institute of Oncology, Division of Medical Oncology, Milano, IT
A. Dietz, University of Leipzig, Department of Otolaryngology, Leipzig, DE
C. Faivre-Finn, Christie Hospital NHS Foundation Trust, Department of Clinical Oncology, Manchester, UK
M.F. Fey, University Hosptal, Clinic for Medical Oncology, Berne, CH
K. Fizazi, Institut Gustave Roussy, Department of Medicine, Villejuif, FR
W. Gatzemeier, Humanitas Clinical Institute, Breast Unit, Rozzano, IT
M. Ghielmini, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
A. Glaus, Tumor-Center ZETUP St. Gallen, Department of Medical Oncology, St. Gallen, CH
J. Gligorov, CancerEst APHP Tenon, Departement of Medical Oncology, Paris, FR
A. Goldhirsch, European Institute of Oncology, Department of Medicine, Milano, IT 
A. Hoy, Consultant in Palliative Medicine, Lead for Advanced Communication Skills SWSH, Epsom, UK
A. Horwich, The Royal Marsden Hospital, Department of Radiotherapy, Sutton, UK 
A. Margulies, Clinical Oncology Nurse, EONS Executive Board Member, Zurich, CH
K. Öberg, University Hospital, Department of Endocrine Oncology, Uppsala, SE
N. Pavlidis, University of Ioannina, Division of Medical Oncology, Ioannina, GR
R. Popescu, Hirslanden Clinic, Tumor Center, Department of Medical Oncology, Aarau, CH 
G.J. Poston, Aintree University Hospital, Dept. of Surgery, Liverpool, UK
T. Powles, Barts and the London NHS Trust, Department of Medical Oncology, London, UK
P. Rougier, European Hospital Georges Pompidou, Department of Digestive Oncology, Paris, France
D. Schrijvers, Ziekenhuisnetwerk Antwerpen-Middelheim, Department of Haemato-Oncology, Antwerp, BE
D. Sebag-Montefiore, University of Leeds, Leeds Cancer Centre, Department of Clinical Oncology, Leeds, UK
E. Senkus-Konefka, Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdansk, PL
C. Sessa, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
L. Sharp, Karolinska University Hospital, Section for Nursing, Stockholm, SE
R.A. Stahel, University Hospital Zurich, Clinic and Policlinic for Oncology, Zurich, CH
T. Sulser, University of Zurich, Division of Urology, Zurich, CH
C. Svedman, Genomic Health International, , Geneva CH
E. Van Cutsem, University Hospital Gasthuisberg, Digestive Oncology Unit, Leuven, BE
J.B. Vermorken, University Hospital Antwerp, Department of Oncology, Edegem, BE
G. Viale, European Institute of Oncology, Department of Pathology, and University of Milano, Milano, IT
W. Weder, University Hospital Zurich, Division of Thoracic Surgery, Zurich, CH

2 April

3 April

4 April

5 April

6 April

7 April